ライフサイエンスコーパス: nitric oxide donor

1 ts, and compared its effects with those of a nitric oxide donor.

2 e relaxing effect of high concentration of a nitric oxide donor.

3 ine was sensitive to sodium nitroprusside, a nitric oxide donor.

4 sed to evaluate vasodilation to an exogenous nitric oxide donor.

5 CGRP in the blood following challenge with a nitric oxide donor.

6 attachment of an organic nitrate moiety as a nitric oxide donor.

7 done with 100 microM sodium nitroprusside, a nitric oxide donor.

8 n be experimentally applied to tissues using nitric oxide donors.

9 analog (8-bromo-cGMP) to mimic the effect of nitric oxide donors.

10 redox cycling compound paraquat, but not to nitric oxide donors.

11 ther N-hydroxyurea analogues may be superior nitric oxide donors.

12 ors of nitric oxide synthase and enhanced by nitric oxide donors.

13 arallel experiments included the addition of nitric oxide donor (0.3 or 1.0 mM SNAP or PAPA-NO) to pe

14 ith IFN-gamma and TNF-alpha or the synthetic nitric oxide donor 2,2'-(hydroxynitrosohydrazino)bis-eth

15 Interestingly, the nitric oxide donor 3-(2-hydroxy-2-nitroso-1-propylhydraz

16 We used the nitric oxide donor 3-morpholino-sydnonimine (SIN-1) or t

17 Nevertheless, the pharmacologic nitric oxide donors 3-morpholino-sydnonimine and S-nitro

18 volving therapies, such as gene transfer and nitric oxide donor administration, which target vein gra

19 The diazeniumdiolate nitric oxide donor agent 1-diethyl-2-hydroxy-2-nitroso-h

20 Ca2+ signaling by exogenous application of a nitric oxide donor and found that nitric oxide induced a

21 d plasticity induced by the combination of a nitric oxide donor and hMSC therapy.

22 K-Cl cotransport (KCC) is activated by nitric oxide donors and appears to be regulated by the c

23 guanosine monophosphate levels compared with nitric oxide donors and BAY41-2272 (about 10-fold versus

24 ed with soluble guanylyl cyclase activators (nitric oxide donors and BAY41-2272) and sildenafil.

25 In a previous study, we showed that nitric oxide donors and N-acetylcysteine, either alone o

26 th those produced by the dextroisomer, other nitric oxide donors and nitric oxide itself.

27 A wide variety of nitric oxide donors and S-nitrosating agents protect the

28 ide the development of new hydroxyurea-based nitric oxide donors and sickle cell disease therapies.

29 s are forced to generate peroxynitrite using nitric oxide donors and superoxide-generating redox cycl

30 +/-2.5 micromol/L at 12 hours, P=NS) despite nitric oxide donors and the excess ET-1 in HF-HP patient

31 Reactive free radical species generated by nitric oxide donors and the interaction of advanced glyc

32 niscal cell TGase activity was stimulated by nitric oxide donors and tumor necrosis factor-alpha, but

33 Nitric oxide donors (and cell-permeant cGMP analogues) a

34 c oxide), sodium nitroprusside (an exogenous nitric oxide donor), and verapamil (a calcium channel bl

35 rotected beta cells in vitro from cytokines, Nitric oxide donor, and H2O2.

36 olangiocytes with proinflammatory cytokines, nitric oxide donors, and endoplasmic reticulum stressors

37 Na,K-ATPase activity did not respond to nitric oxide donors, and the free radical-dependent step

38 Hydroxylamine, a nitric-oxide donor, and 8-bromo-cGMP, a membrane-permean

39 Nitric oxide donors are often used experimentally in att

40 Nitroglycerin, an exogenous nitric oxide donor, caused a selective vasodilatory effe

41 echnologies, including biodegradable stents, nitric oxide donor-coated stents, and a new generation o

42 sted S-nitrosylation induced in vitro by the nitric oxide donor compound S-nitroso-L-glutathione, fai

43 tance to paraquat, but not for resistance to nitric oxide donor compounds in vitro, resistance to mac

44 he 8-bromo-cGMP did not mimic the effects of nitric oxide donors (DETA-NO) on apoptosis.

45 s endogenous (coadministration of NMDA and a nitric oxide donor, diethylenetriamine NONOate) peroxyni

46 ll lines (DU145, PC-3, CL-1, and LNCaP) with nitric oxide donors (e.g. (Z)-1-[2-(2-aminoethyl)-N-(2-a

47 Topical sodium nitrite, a known nitric oxide donor, enhances blood flow in ulcers and ha

48 Addition of a nitric oxide donor, GSNO, to WT but not CypD(-/-) MEFs p

49 ased the amount of active gelatinases, while nitric oxide donors had no noticeable effect.

50 All three nitric oxide donors had similar effects resulting in dos

51 The nitric oxide donor hydroxylamine (NH2OH) induced a trans

52 The commonly used nitric oxide donor, hydroxylamine (NH(2)OH), can block o

53 tase (XOR) inhibition (i.e., allopurinol) or nitric oxide donors (i.e., S-nitrosoglutathione, GSNO).

54 dicating that its nitrate tether served as a nitric oxide donor in vivo.

55 rates the potential use of platelet-specific nitric oxide donors in the treatment of thromboembolic d

56 hese effects were similar to those seen with nitric oxide donors in this study and previous work from

57 hion to thiol redox reagents in vitro and to nitric oxide donors in vivo.

58 h muscle has led to an interest in employing nitric oxide-donors in the treatment of preterm labor.

59 ne], NOC-15 [PAPA-NO], 0.3 or 1.0 mM of each nitric oxide donor) in the presence/absence of methylene

60 We found that various nitric oxide donors, including diethylamine NONOate (DEA

61 Phenylephrine-induced contraction and nitric oxide donor-induced relaxation were similar in al

62 nd abrogates forearm blood flow responses to nitric oxide donor infusions.

63 DETA NONOate, a nitric oxide donor, inhibited the basal, angiotensin-II-

64 Treatment of Hdm2 with a nitric oxide donor inhibits Hdm2-p53 binding, a critical

65 ectroencephalographic response to a cerebral nitric oxide donor (intravenous sodium nitrite) to explo

66 Vaginal administration of the nitric oxide donor isosorbide mononitrate can induce eff

67 In vitro treatment of splenocytes with a nitric oxide donor led to a decreased STAT1 IFN response

68 e threshold for spreading acidification, and nitric oxide donors lowered the threshold.

69 inflammatory and antiviral role in colds and nitric oxide donors may represent a novel therapeutic ap

70 telet free cytosolic calcium, such as direct nitric oxide donors, may be more potent overall than asp

71 HF-HP patients received nitric oxide donors (nitroglycerin/sodium nitroprusside)

72 The direct nitric oxide donor nitroprusside is an effective, safe t

73 Soluble nitric oxide donors (NO/nucleophile adducts-NONOates) ar

74 A nitric oxide-donor, NOC-15 ((Z)-1-[N-(3-ammoniopropyl)-N

75 a cGMP analogue recapitulated the effects of nitric oxide donors on cytokine secretion.

76 , 8-bromo-cGMP, recapitulated the effects of nitric oxide donors on myocyte cytokine secretion.

77 e to cytokine stimulation, or by a synthetic nitric oxide donor, on replication of obligately intrace

78 In vitro, GAPC1 was inactivated by either nitric oxide donors or hydrogen peroxide, but no inhibit

79 Microinjection of nitric oxide donors or recombinant nitric oxide synthase

80 with cytokines but not in cells treated with nitric oxide donors or with endoplasmic reticulum stress

81 macological approaches include drugs such as nitric oxide donors, phosphodiesterase inhibitors, endot

82 We now show that nitric oxide donors positively regulate a chromosomal fl

83 dition of S-nitroso-N-acetylpenicillamine, a nitric oxide donor, prevented VEGF-induced eNOS up-regul

84 Nitric oxide donors produced a dose-dependent increase i

85 In addition, incubation with a nitric oxide donor promoted this interaction in vitro.

86 Conversely, low levels of a nitric oxide donor reduced HIF-1alpha expression in norm

87 Nitric oxide donor-related effects were ablated by pretr

88 Exposure of Calu-3 cells to nitric oxide donors resulted in the nitration of a numbe

89 th S-nitroso-N-acetylpenicillamine (SNAP), a nitric oxide donor, resulted in a decrease in ADH activi

90 impaired dilations to acetylcholine and the nitric oxide donor S-nitroso-N-acetyl-D,L-penicillamine

91 ion induced by either NTG or the spontaneous nitric oxide donor S-nitroso-N-acetylpenicillamine (SNAP

92 inhibitor 7-nitroindazole (7NI; 1 mM) or the nitric oxide donor S-nitroso-N-acetylpenicillamine (SNAP

93 In both HeLa and COS-7 cells, the nitric oxide donor S-nitroso-N-acetylpenicillamine incre

94 he urea transporter-A promoter, in which the nitric oxide donor S-nitroso-N-acetylpenicillamine reduc

95 cluding the calcium ionophore ionomycin, the nitric oxide donor S-nitroso-N-acetylpenicillamine, and

96 r isotonic or hypertonic conditions with the nitric oxide donor S-nitroso-N-acetylpenicillamine.

97 d that systemic administration of endogenous nitric oxide donor S-nitrosoglutathione in mice blocked

98 cellular respiration by the addition of the nitric oxide donors S-nitroso-N-acetyl-DL-penicillamine

99 well) and challenged with either vehicle or nitric oxide donor (S-nitroso-N-acetyl-penicillamine [SN

100 and compare these effects with those of the nitric oxide donor, S-nitroso-N-acetylpenicillamine, an

101 ease in M-CSF expression was attenuated by a nitric oxide donor, S-nitrosoglutathione (GSNO), and by

102 Exposure of slices to the nitric oxide donors, S-nitroso-N-acetylpenicillamine and

103 Aorta treated with the nitric oxide donors, S-nitroso-N-acetylpenicillamine and

104 L6 myotubes treated with nitric oxide donors, S-nitroso-N-penicillamine (SNAP, 25

105 Nitric oxide donors slowed the frequency of pacemaker cu

106 The addition of the nitric oxide donors SNP or SNAP to mitogen-stimulated VS

107 The exogenous nitric oxide donor sodium nitroprusside (1 micromol/L; n

108 ease in RBF (P < 0.05; n = 5) induced by the nitric oxide donor sodium nitroprusside (15 nmol).

109 We compared the effects of the nitric oxide donor sodium nitroprusside (SNP) on intrace

110 Addition of the nitric oxide donor sodium nitroprusside also produced os

111 d acetylcholine, the endothelium-independent nitric oxide donor sodium nitroprusside and the endothel

112 n of ADP-induced platelet aggregation by the nitric oxide donor sodium nitroprusside and the phosphod

113 (P < 0.05) and sensitivity (P < 0.05) to the nitric oxide donor sodium nitroprusside were reduced in

114 duced in SH-SY5Y cells after exposure to the nitric oxide donor sodium nitroprusside, and betaine was

115 synthase was shown to be inactivated by the nitric oxide donor sodium nitroprusside.

116 Furthermore, the nitric oxide donors sodium nitroprusside and S-nitrosogl

117 s of lipopolysaccharide were mimicked by the nitric oxide donors sodium nitroprusside and spermine NO

118 mg kg(-1)) or increasing bolus doses of the nitric oxide donor, sodium nitroprusside (SNP), were stu

119 attenuating lipid peroxidation caused by the nitric oxide donor, sodium nitroprusside (SNP).

120 methylarginine [8 mumol/min], coinfused with nitric oxide donor, sodium nitroprusside [90 to 900 ng/m

121 of NGF on ROS production was mimicked by the nitric oxide donor, sodium nitroprusside, and was blocke

122 only weakly enhanced in the presence of the nitric oxide donor, sodium nitroprusside.

123 This was confirmed with the use of the nitric oxide donor, spermine-nitric oxide complex, in an

124 Nitric oxide donors such as glyceryl trinitrate (GTN) ha

125 Currently available nitric oxide donors such as glyceryl trinitrate or isoso

126 Nitrates such as nitroglycerin (GTN) and nitric oxide donors such as S-nitrosothiols are clinical

127 pase-3 activation and cell survival, whereas nitric oxide donors (such as 1-propamine 3-(2-hydroxy-2-

128 response to exogenous as well as endogenous nitric oxide donors suggests that the abnormality is due

129 S-nitrosoglutathione (GSNO) is a nitric oxide donor that appears to have relative platele

130 Nitroglycerin is a nitric oxide donor that exerts potent effects on the car

131 A-MB-231 cells treated with Angeli's salt, a nitric oxide donor that has been shown to inhibit breast

132 S-nitrosoglutathione (GSNO) is a nitric oxide donor that may exert antioxidant, anti-infl

133 In addition to their role as nitric oxide donors, there is growing evidence that thes

134 This may be prevented by the addition of a nitric oxide donor to NSAIDs.

135 tudies included examining the ability of: a) nitric oxide "donors" to alter nuclear factor kappa B (N

136 eatment for sickle cell anemia and acts as a nitric oxide donor under oxidative conditions in vitro.

137 The hepato-selective nitric oxide donor, V-PYRRO/NO, reduced hepatic resistan

138 The effects of nitric oxide donors were mimicked by membrane-permeable

139 charide confirmed that cytokine responses to nitric oxide donors were not related to lipopolysacchari

140 Three nitric oxide donors were used: spermine NONOate (SP), (+

141 well as relaxation produced by exposure to a nitric oxide donor, were similar in wild-type and null m

142 nhanced by stimulation of cGMP synthesis via nitric oxide donors, whereas specific PDE2 inhibition pa

143 SNP, a nitric oxide donor, which had little toxic effect by its

144 ectiveness of S-nitrosoglutathione (GSNO), a nitric oxide donor with relative platelet specificity, i

145 Nitric oxide donors with longer half-lives could prove b

146 of human marrow stromal cells (hMSC) with a nitric oxide donor, (Z)-1-[N-(2-aminoethyl)-N-(2-ammonio

147 We report that administration of a nitric oxide donor, (Z)-1-[N-(2-aminoethyl)-N-(2-ammonio